XL Therapeutics
Treatment of Conditions Caused by Deficiencies in WAS Protein Expression
Health Tech & Life Sciences
Non Active, May 2019 ceased to operate
Company Overview
Snapshot
Founded in May 2016 by Rachel Eran and Mira Barda-Saad, XL Therapeutics operates with 1–10 employees. The company secured seed funding in May 2017 from FutuRx. The company ceased operations in May 2019.
Business overview
XL Therapeutics is a biopharmaceutical company focused on developing small molecule compounds. The company aims to treat patients suffering from Wiskott-Aldrich syndrome (WAS) and X-linked thrombocytopenia, rare primary human immunodeficiencies caused by the absence or suboptimal function of the WAS protein (WASp). It operates within the Health Tech & Life Sciences sector, specifically targeting the pharmaceutical industry with its drug discovery and development efforts.
Company Intelligence Q&A
- When was XL Therapeutics founded?
- XL Therapeutics was founded in May 2016.
- Who are the founders of XL Therapeutics?
- The co-founders of XL Therapeutics are Rachel Eran and Mira Barda-Saad.
- What is the primary focus of XL Therapeutics?
- XL Therapeutics focuses on developing small molecule compounds to treat conditions caused by deficiencies in WAS protein expression, such as Wiskott-Aldrich syndrome and X-linked thrombocytopenia.
- What is the current operational status of XL Therapeutics?
- XL Therapeutics is non-active and ceased operations in May 2019.
- Which investor participated in XL Therapeutics' seed funding round?
- In May 2017, XL Therapeutics received seed funding from FutuRx.